Related Experiment Video
Updated: Aug 1, 2026
07:28
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
[Inhaled corticosteroids for COPD]
1Universitair Medisch Centrum St Radboud, afd. Longziekten, Postbus 9101, 6500 HB Nijmegen. r.dekhuijzen@long.umcn.nl
Nederlands Tijdschrift Voor Geneeskunde
|August 5, 2003
Summary
Inhaled corticosteroids (ICS) benefit COPD patients by reducing exacerbations and improving quality of life, though not lung function decline. A trial of ICS is recommended for specific patient subgroups with moderate to severe COPD.
Area of Science:
- Pulmonology
- Respiratory Medicine
- Pharmacology
Context:
- Chronic Obstructive Pulmonary Disease (COPD) management involves significant use of inhaled corticosteroids (ICS), despite ongoing debate regarding their efficacy.
- The inflammatory profile in COPD, characterized by macrophages, T-lymphocytes, and specific cytokines, is less responsive to corticosteroids than in asthma.
Purpose:
- To evaluate the role and efficacy of inhaled corticosteroids (ICS) in managing Chronic Obstructive Pulmonary Disease (COPD).
- To identify patient subgroups who may benefit from ICS therapy and to define optimal trial treatment parameters.
Summary:
- Placebo-controlled studies demonstrate ICS improve exacerbation frequency/severity and quality of life in COPD, but do not halt accelerated lung function decline.
- ICS discontinuation was linked to exacerbations in a subgroup of patients.
- A one-year ICS trial is suggested for moderate to severe COPD patients, particularly those with asthma/allergy signs, hyperresponsiveness, or recurrent exacerbations, focusing on exacerbations and symptoms.
Impact:
- Findings support considering ICS trials in selected COPD patients, guiding personalized treatment strategies.
- Combined ICS and long-acting beta-2 agonist therapy may offer additional benefits for COPD symptom management and exacerbation reduction.
Related Concept Videos
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...